Guggenheim Maintains Buy on MBX Biosciences, Raises Price Target to $150
Benzinga Newsdesk 4 weeks ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Seamus Fernandez maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $88 to $150.
Guggenheim analyst Seamus Fernandez maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $88 to $150.